drugset / Trial / NCT00504023
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Completed
8 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collabOhio State University · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.
Timeline
- Start
- 2007-04
- Primary completion
- 2018-01
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imiquimod | Other / unclassified | — | Topical |